FDA Approves Oxlumo

FDA Approves Oxlumo (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 24, 2020– Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics

Read more